The Relationship between Duration of Treatment and Drug Side Effects on SGOT and SGPT Levels in Pulmonary Tuberculosis Patients during the Continuation Phase at RSUD Dr. H. Abdul Moeloek
DOI:
https://doi.org/10.35451/jfm.v9i1.3904Keywords:
duration of treatment, drug side effects, tuberculosis, SGOT, SGPTAbstract
Backrgound: Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Its treatment consists of two phases: the intensive phase, which includes rifampicin, isoniazid, pyrazinamide, and ethambutol, and the continuation phase, which consists of rifampicin and isoniazid. Long-term use of anti-tuberculosis drugs may cause various adverse effects, with hepatotoxicity being one of the most serious. Objective: This study aimed to determine the relationship between the duration of treatment and drug side effects on SGOT and SGPT levels in pulmonary tuberculosis patients during the continuation phase at RSUD Dr. H. Abdul Moeloek. Methods: This study employed a retrospective, observational, non-experimental cross-sectional design. Data were collected from the medical records of pulmonary tuberculosis patients treated between January and August 2025, with a total sample size of 120 patients. Data were analyzed using the Chi-square test. Results: The results showed a significant relationship between treatment duration and SGOT/SGPT levels p = 0.001 (p < 0.05). A significant relationship was also found between drug side effects and SGOT/SGPT levels p = 0.001 (p < 0.05). Conclusion: It can be concluded that patients receiving anti-tuberculosis treatment for more than four months are at a higher risk of elevated SGOT and SGPT levels. Furthermore, higher SGOT and SGPT levels are associated with a greater likelihood of experiencing severe drug side effects.
Downloads
References
[1] Bajuradja, I., & Singh, G. (2020). Mekanisme Hepatotoksisitas dan tatalaksana Tuberkulosis Pada Gangguan Hati. Indonesia Journal Chest, 7(2), 55–64.
[2] Chairini, S., & Widodo. (2020). Gambaran Pemeriksaan Kadar SGOT dan SGPT pada Penderita Tuberkulosis Paru. Jurnal Laboratorium Medis , 2(1), 18–21.
[3] Irawan, M. P., Oktavia, T., Pangestu, M. A. P., & Sholikasra, L. (2024). Pemeriksaan Sgot, Sgpt Dan Kreatinin Pasien Tuberkulosis Paru Pengobatan Fase Intensif Dan Lanjutan Di Kecamatan Tampan. AKSELERASI: Jurnal Ilmiah Nasional, 6(3), 26–30.
[4] Josephina, S. M., & Walandow, D. (2019). Neuropati Optik Bilateral Pasca Terapi Etambutol. Jurnal Biomedik (Jbm), 5(1), 58–63.
[5] Kementerian Kesehatan RI. (2020). Pedoman Nasional Pelayanan Kedokteran: Tata Laksana Tuberkulosis.
[6] Kementerian Kesehatan RI. (2024). Laporan Situasi Tuberkulosis Indonesia Tahun 2024. In Jakarta: Kementerian Kesehatan RI.
[7] Komang, N., Renita, A., Setyorini, A., Mayangsari, M., & Putu, I. G. A. (2025). Characteristics Of Body Weight Changes In Pediatric Tuberculosis Receiving Anti-Tuberculosis Drugs At Prof. Dr. I.G.N.G. Ngoerah General Hospital From 2021 To 2024. Jurnal Kesehatan Tambusai, 6(September), 9589–9601.
[8] Ningsih, A. S. W., Ramadhan, A. M., & Rahmawati, D. (2022). Kajian Literatur Pengobatan Tuberkulosis Paru dan Efek Samping Obat Antituberkulosis di IndonesiaLiterature. Proceeding of Mulawarman Pharmaceuticals Conferences, 231–241.
[9] Putri, Randita, V., Muslim, Z., & Susilo, Iqoranny, A. (2024). Analisis Kejadian Efek Samping Obat Anti Tuberkulosis Di Kota Bengkulu. Journal Of Nursing and Public Health, 12(1), 187–191.
[10] Rahayu, S. E., Sukeksi, A., & Nuroini, F. (2017). Hubungan Kadar SGOT-SGPT Pada Pasien TB Pengobatan Fase Awal Di Puskesmas Pati. Repository Unimus, 1–6.
[11] Rahman, M. M., Setyawati, T., Sarifuddin, & Wahyuni, R. D. (2023). Mekanisme Oat Dalam Tubuh Yang Mengakibatkan Risiko Dili (Drug-Induced Liver Injury). Medical Profession (MedPro), 5(1), 41–47.
[12] Rosamarlina, R., Lisdawati, V., Banggai, C. E., Darayani, D., Pakki, T. R., Rogayah, R., & Murtiani, F. (2019). Monitoring Efek Samping Obat Anti Tuberkulosis di Poli TB DOTS RSPI Prof. Dr. Sulianti Saroso. The Indonesian Journal of Infectious Diseases, 5(2), 10–20.
[13] Sabiti, F. B., & Sa’dyah, N. A. C. (2022). The Relationship Between Side Effects of Tuberculosis Drug Use and SGOT/ SGPT Value Of Intensive Phase Patients. Jurnal Farmasi Sains Dan Praktis, 8(3), 281–285.
[14] Salamah, S. H., Faridah, I. N., Dania, H., & Kristina, S. A. (2026). Evaluasi Kepatuhan Pengobatan Pasien TB Paru Aktif dan TB Paru Laten Menggunakan MARS-5 dan Pill Count di Puskesmas Playen I , Evaluation of Treatment Adherence in Patients with Active and Latent Pulmonary TB Using MARS-5 and Pill Count at Playen I , Kara. 15(1), 25–38.
[15] Salbiah, S., Diah Lestari, Dina Indarsita, Halimah Fitriani Pane, & Yasmine Amira Fadila. (2024). Analisis Kadar Serum Glutamic Piruvic Transaminase Dan Serum Glutamic Oxaloacetic Transaminase Pada Pasien Tuberkulosis Yang Menjalani Pengobatan Obat Anti Tuberkulosis. Jurnal Ilmiah PANNMED (Pharmacist, Analyst, Nurse, Nutrition, Midwivery, Environment, Dentist), 19(1), 147–152.
[16] Sari, D. P., & Andriani, V. (2024). Kajian Hubungan Penggunaan Obat Antituberkulosis Fase Awal Terhadap Kadar Sgot-Sgpt Pada Pasien Tbc Paru Di Rsud Pasar Rebo Jakarta. Jurnal Kesehatan Tambusai, 5(4), 10783–10792.
[17] Sari, D. P., & Sitompul, R. E. (2025). Pengaruh Terapi OAT (Obat Anti Tuberkulosis) dan Faktor Risiko Terhadap Kejadian Hepatotoksisitas pada Pasen TB Paru di RSUD Pasar Rebo. Jurnal Surya Medika, 11(3), 13–21.
[18] Savitri, E. W., Sius, U., & Sudarso, M. (2021). Hubungan efek samping OAT dengan motivasi pasien TB paru untuk melanjutkan pengobatan. Holistik Jurnal Kesehatan, 15(3), 391–404.
[19] Seniantara, I. K., Ivana, T., & Gabrilinda, A. Y. (2018). Pengaruh Efek Samping OAT (Obat Anti Tuberculosis) Terhadap Kepatuhan Minum Obat Pada Pasien TBC Di Puskesmas. Jurnal Keperawatan Suaka Insan (Jksi), 3(2), 1–12.
[20] Setyowati, M. (2021). Hubungan Lama Penggunaan, Dosis, Efek Samping Obat Pada Pasien Tuberkulosis Fase Lanjutan Terhadap Nilai SGOT/SGPT di Rumah Sakit Islam Sulta Agung Semarang. Karya Tulis Ilmiah, Semarang, 83.
[21] Wabula, S., Widyantara, A. B., & Astuti, T. D. (2024). Analisis Kadar SGOT Dan SGPT Pada Pasien Tuberkulosis Dalam Pengobatan OAT Di RSU PKU Muhammadiyah Yogyakarta. Jurnal Kesehatan Tambusai, 5(3), 9152–9158.
[22] Yudhaswara, N. A., Susilawati, N. M., & Udju, S. D. (2024). Hubungan Lama Pengobatan Dengan Kadar Sgot Dan Sgpt Pada Pasien Tuberkulosis. Journal of Nursing and Health, 9(3), 299–306.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Faisal Al Kahfi, Annisa Primadiamanti, Shinta Wulandari
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
